Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2016

Early pregnancy vitamin D status and risk of preeclampsia
Robert C. Strunk
Washington University School of Medicine in St. Louis

Leonard B. Bacharier
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Strunk, Robert C.; Bacharier, Leonard B.; and et al, ,"Early pregnancy vitamin D status and risk of
preeclampsia." The Journal of Clinical Investigation. 126,12. 4702-4715. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5476

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Downloaded from http://www.jci.org on January 4, 2017. https://doi.org/10.1172/JCI89031

CLINICAL MEDICINE

The Journal of Clinical Investigation  

Early pregnancy vitamin D status and risk
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BACKGROUND. Low vitamin D status in pregnancy was proposed as a risk factor of preeclampsia.
METHODS. We assessed the effect of vitamin D supplementation (4,400 vs. 400 IU/day), initiated early in pregnancy (10–18
weeks), on the development of preeclampsia. The effects of serum vitamin D (25-hydroxyvitamin D [25OHD]) levels on
preeclampsia incidence at trial entry and in the third trimester (32–38 weeks) were studied. We also conducted a nested casecontrol study of 157 women to investigate peripheral blood vitamin D–associated gene expression profiles at 10 to 18 weeks in
47 participants who developed preeclampsia.
RESULTS. Of 881 women randomized, outcome data were available for 816, with 67 (8.2%) developing preeclampsia. There was
no significant difference between treatment (N = 408) or control (N = 408) groups in the incidence of preeclampsia (8.08% vs.
8.33%, respectively; relative risk: 0.97; 95% CI, 0.61–1.53). However, in a cohort analysis and after adjustment for confounders,
a significant effect of sufficient vitamin D status (25OHD ≥30 ng/ml) was observed in both early and late pregnancy compared
with insufficient levels (25OHD <30 ng/ml) (adjusted odds ratio, 0.28; 95% CI, 0.10–0.96). Differential expression of 348
vitamin D–associated genes (158 upregulated) was found in peripheral blood of women who developed preeclampsia (FDR
<0.05 in the Vitamin D Antenatal Asthma Reduction Trial [VDAART]; P < 0.05 in a replication cohort). Functional enrichment
and network analyses of this vitamin D–associated gene set suggests several highly functional modules related to systematic
inflammatory and immune responses, including some nodes with a high degree of connectivity.
CONCLUSIONS. Vitamin D supplementation initiated in weeks 10–18 of pregnancy did not reduce preeclampsia incidence in
the intention-to-treat paradigm. However, vitamin D levels of 30 ng/ml or higher at trial entry and in late pregnancy were
associated with a lower risk of preeclampsia. Differentially expressed vitamin D–associated transcriptomes implicated the
emergence of an early pregnancy, distinctive immune response in women who went on to develop preeclampsia.
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Introduction

Preeclampsia is a multisystem complex disease of pregnancy with
grave maternal-fetal and neonatal consequences that complicates
up to 8% of pregnancies (1, 2). Low vitamin D status, among other
risk factors, is linked to the development of preeclampsia. Systematic reviews and meta-analyses have concluded that low serum
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vitamin D levels (25-hydroxyvitamin D [25OHD]) in pregnancy
are associated with a higher risk of preeclampsia and suggest a
preventive role of vitamin D supplementation (3–6). However, a
recent meta-analysis of the 3 vitamin D supplementation randomized clinical trials (RCTs) on pregnancy outcomes found no association between increased serum vitamin D levels and preeclampsia risk (7). Although these studies vary in the dose of vitamin D
supplementation (400–4,000 IU/day) and in the baseline and
attained vitamin D levels, it is most important to note that all of
the RCTs started the intervention after 20 weeks of gestation. It
is noted that this meta-analysis did not include the results of the
National Institute of Child Health and Development (NICHD)
trial that started vitamin D supplementation before 20 weeks of
gestation (8). A meta-analysis of the abnormal maternal biomarkers found during the first trimester of pregnancy in women who
developed preeclampsia and the findings of previous studies on
the association of preeclampsia and low vitamin D status in early pregnancy suggest the necessity of early serum vitamin D level
surveillance and modification in pregnancy (5, 9). As such, our trial, the Vitamin D Antenatal Asthma Reduction Trial (VDAART),
investigated the effect of early pregnancy vitamin D supplementation and both early and late pregnancy 25OHD levels on the risk
of preeclampsia, one of the a priori–defined outcomes of the trial.
Previous investigations have also shown the effect of vitamin
D levels on peripheral blood gene expression during pregnancy
and in preeclampsia (10, 11). Global gene expression profiling has
the potential to identify representative pathway genes that might
point to the underlying molecular mechanism of preeclampsia
(12–15). Therefore, we performed a nested case-control study in
the VDAART to identify vitamin D gene signatures related to preeclampsia during early pregnancy. There is increasing evidence
that disease signature and causal genes do not distribute randomly on the molecular interaction network (interactome), but rather
interact in similar biological pathways (16, 17). Accordingly, we
applied a molecular interaction network approach using information from differential expression and a protein-protein interaction
network to identify interacting key drivers (preeclampsia module)
of the vitamin D gene signatures.

Results

Low vitamin D status in early pregnancy and throughout is associated with a higher risk of preeclampsia. Of 9,268 women who were
screened, 881 were randomized. After exclusion of 5 ineligible women, 440 were assigned to receive vitamin D and 436 to
receive placebo (Figure 1). A total of 32 women in the treatment
group and 28 in the placebo group (60 of 876, 6.8% overall) were
lost to follow-up.
Among the baseline characteristics, gravidity was significantly different between the 2 study groups (Table 1). Vitamin D levels
during the third trimester in the treatment group amounted to 39
± 15 ng/ml versus 27 ± 11 ng/ml in the placebo group (P < 0.0001).
No side effects or adverse events were reported in association with
vitamin D supplementation. Preeclampsia occurred in 33 women
in the treatment group (8.08%) as compared with 34 women in the
placebo group (8.33%) (relative risk [RR], 0.97; 95% CI, 0.61–1.53).
While vitamin D supplementation increased 25OHD levels in the
third trimester, no reduction in the rate of preeclampsia was seen
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in the vitamin D treatment group as compared with that in the placebo group. However, women who had sufficient vitamin D levels
(at least 30 ng/ml) in both early and late pregnancy, regardless of
treatment group, showed a significantly lower incidence of preeclampsia as compared with those who had an insufficient level at
these time points (2.25% vs. 11.92%; RR, 0.20; CI, 0.06–0.66; P <
0.008). Within the treatment and placebo control groups, trends
toward a decreased occurrence of preeclampsia were observed
among women who had sufficient vitamin D status (≥30 ng/ml) in
both early and late pregnancy (high-high 25OHD: odds ratio [OR],
0.6; CI, 0.35–1.06; P = 0.08 and OR, 0.35; CI, 0.16–0.78; P = 0.01,
respectively). The pooled estimate of the OR in the intention-totreat (ITT) population was 0.55 (CI, 0.37–0.82; P < 0.003). After
covariate adjustment (Table 2), women with sufficient vitamin D
concentrations at both 10 to 18 and 32 to 38 weeks of gestation had
a substantially reduced risk of preeclampsia (adjusted OR, 0.28;
CI, 0.08–0.96; P = 0.04). 25OHD serum concentrations in early
pregnancy were a predictor of preeclampsia (adjusted OR, 0.96;
CI, 0.93–0.99; P =0.025), such that a 10-, 20-, or 30-unit increase
(ng/ml) was associated with a 33%, 54%, and 70% reduction in
the risk of preeclampsia, respectively (adjusted OR10-unit = 0.67;
95% CI, 0.47–0.95; adjusted OR20-unit = 0.46; 95% CI, 0.22–0.90;
adjusted OR30-unit = 0.30; 95% CI, 0.16–0.85, respectively). No
occurrence of preeclampsia was noted in women with a baseline
serum value above 37 ng/ml. Accordingly, the adjusted estimated probability of preeclampsia was less than 0.05 at an approximate vitamin D serum level of 40 ng/ml (100 nmol/l) during early
pregnancy (Figure 2).
Early pregnancy vitamin D status modulates the expression of
preeclampsia transcriptome signatures. Marginal comparisons of
distributions of maternal age, race, and gestational age at enrollment in the VDAART discovery or replication cohort were consistent with the effectiveness of the matching procedures used (all
P > 0.05, minimum P = 0.12; Table 3). 25OHD serum levels were
significantly lower in women in the VDAART discovery cohort
who developed preeclampsia (P = 0.004). Overall, in the discovery cohort, 119 subjects had insufficient vitamin D status (<30 ng/
ml, 41 with preeclampsia), and 38 subjects had sufficient vitamin
D status (≥30 ng/ml, 6 positive for preeclampsia), respectively
(Figure 3). In the VDAART cohort, 2,829 genes were identified as
differentially expressed among women with 25OHD levels dichotomized at 30 ng/ml (1,081 upregulated). The pregnant women
who developed preeclampsia had 1,547 genes (611 upregulated)
that were differentially expressed relative to those of controls.
The intersection of the vitamin D gene signatures and the preeclampsia gene signatures represented vitamin D gene signatures
associated with preeclampsia, i.e., 1,323 unique genes (592 upregulated). Of these genes, 348 (158 upregulated) were differentially expressed in peripheral blood in preeclamptic subjects versus
controls in the OMEGA study (marginal per gene, P < 0.05, Figure 3 and Supplemental Table 1; supplemental material available
online with this article; doi:10.1172/JCI89031DS1). From the total
348 replicated differentially expressed genes, 33 genes were identified in a database search, and manual curation of the literature
revealed an additional 107 genes with a prior known association
with preeclampsia (140 of 348, 40.23%; Supplemental Table 2).
The replicated gene signatures also showed tissue-specific enrichjci.org   Volume 126   Number 12   December 2016
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Figure 1. VDAART preeclampsia CONSORT diagram.

ment in placenta (P < 0.0001); according to the Human Protein
Atlas, 181 genes had evidence of an expression value in placenta
(placenta signatures: 181 of 348 [52.01%], 68 in decidua [19.54%],
15 in trophoblast [4.31%], and 98 [28.16] in both; Figure 4 and Supplemental Table 3).
Interactome mapping demonstrates interacting immunomudulatory gene signatures in early pregnancy in women who develop
preeclampsia. Three hundred two of three hundred forty-eight
4704
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(86.78%) replicated differentially expressed genes were mapped
onto the interactome and demonstrated local clustering in the network (preeclampsia module vs. random expectation, P <0.0001;
Figure 5). We identified the “observable preeclampsia module”
consisting of 143 genes with 552 connections, among them IL8
(also known as CXCL8), MX1, HLA-DP1A, HLA-DBQB1, MMP9,
RPL31, ACTA2, IFI44L, and SERPING1, all of which were previously reported to be in association with preeclampsia (Supple-
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Table 1. Baseline maternal characteristics in the VDAART
Clinical center
San Diego, n (%)
Boston, n (%)
St. Louis, n (%)
Age in years, mean (SD)
<30, n (%)
30–34, n (%)
≥35, n (%)
Gravidity, including in the VDAART, mean (SD)
Gestational age in weeks at enrollment, mean (SD)
Gestational age in weeks at delivery, mean (SD)
BMI at first appointment, mean (SD)
Baseline vitamin D (25OHD) in ng/ml, mean (SD)
Third trimester 25OHD in ng/ml, mean (SD)
Third trimester 25OHD ≥30 ng/ml, n (%)
Mother
Asthma, n (%)
Allergic rhinitis, n (%)
Eczema, n (%)
Race/ethnicity
Black/African-American, n (%)
White/Hispanic, n (%)
White/non-Hispanic, n (%)
Other, n (%)
Education level completed
Lower than high school, n (%)
High school, technical school, n (%)
Some college, n (%)
College graduate/graduate school, n (%)
Marital status
Married, n (%)
Divorced/separated, n (%)
Not married, n (%)
Household income (US $)
<$30,000, n (%)
$30,000–49,999, n (%)
$50,000–74,999, n (%)
$75,000–99,999, n (%)
$100,000–149,000, n (%)
>$150,000, n (%)

4,400 IU (n = 408)

400 IU (n = 408)

P value

136 (33)
118 (29)
154 (38)
27.5 (5.4)
258 (63)
121 (30)
29 (7)
2.6 (1.7)
14.2 (2.8)
38.7 (2.13)
28.9 (7.7) n = 382
23.32 (10.3) n = 405
39.2 (15.34) n = 386
290 (74.2)

141 (35)
125 (31)
142 (35)
27.2 (5.6)
268 (66)
109 (27)
31 (8)
2.3 (1.4)
14.2 (2.7)
38.8 (2.42)
29.0 (7.6) n = 391
22.6 (10.2) n = 406
26.8 (10.74) n = 391
135 (35)

0.68

173 (42)
258 (63)
128 (31)
178 (44)
55 (13)
108 (26)
67 (16)
63 (15)
111 (27)
98 (24)
136 (33)
179 (44)
12 (3)
217 (53)

50 (12)
48 (12)
42 (10)
33 (8)
18 (4)

mental Table 2) and showed the highest degree of connectivity
in the interactome. This module was significantly close to known
signaling pathways for both IL-10 and vitamin D (Z scores –8.6
and –3.8, respectively, P ≤ 0.0001; Figure 6 and Table 4). Gene
ontology (GO) enrichment analysis linked the 348 replicated gene
signatures to several immunologic functions including immune
system process, response, and regulation (N = 109, 83, and 63,
respectively); innate and adaptive immune response (N = 50 and
19, respectively); inflammatory response (N = 35); IL-10 production and negative regulation (N = 8 and 7, respectively); regulation
of cytokine production (N = 25); and type I IFN–signaling pathway
and cellular response to type I IFN (N = 10 and 10, respectively, all

0.34
0.64

corrected P < 0.05; Supplemental
Table 4). Similarly, the observable preeclampsia module was
associated with immune system
process, response, and regulation
(N = 57, 45, and 27, respectively;
all corrected P < 0.05; Supplemental Table 5).

Discussion

In the VDAART, supplementation with vitamin D initiated
between 10 and 18 weeks of
gestation did not reduce the frequency of preeclampsia in the
ITT analysis. However, women
who had sufficient vitamin D
levels (≥30 ng/ml) at enrollment
in early pregnancy and retained
154 (38)
0.17
that status in late pregnancy had
264 (65)
0.66
a significantly lower rate of pre132 (32)
0.76
eclampsia compared with wom177 (43)
0.99
en with insufficient vitamin D
58 (14)
levels (P = 0.04). This finding,
108 (26)
along with the biological signifi65 (16)
cance of the identified peripheral
blood gene expression signatures
39 (10)
0.052
in women who developed pre133 (33)
eclampsia, implicates early preg96 (24)
nancy vitamin D status in the
140 (34)
development of the disease.
Despite
evidence
from
193 (47)
0.59
observational
studies
showing
10 (2)
an association of low vitamin
205 (50)
D status during pregnancy with
preeclampsia (3–6), few random122 (30)
117 (29)
55 (13)
ized trials have examined the
50 (12)
effectiveness of vitamin D sup37 (9)
plementation in pregnancy out31 (8)
comes, particularly in prevent13 (3)
ing preeclampsia (5, 7, 8, 18, 19).
These trials had a smaller sample
size, and in only 1 study was the
therapy initiated approximately
as early as it was in the VDAART
(8). Except for the 1 other trial started early in pregnancy (8) and
a recent trial of vitamin D supplementation after 20 weeks of
gestation (19), the doses of vitamin D used were less than those
in VDAART. No other trial, to our knowledge, has explored the
underlying biological mechanisms using expression profiling and
functional annotation of identified genes.
The inverse association between maternal vitamin D concentrations in early pregnancy and risk of preeclampsia in the
VDAART is consistent with the findings of previous observational studies (20–22). A noteworthy finding of the VDAART is that
a circulating vitamin D level of approximately 40 ng/ml during
pregnancy seems to minimize the vitamin D–associated risk of
0.008
0.86
0.83
0.77
0.29
<0.0001
<0.0001
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vitamin D3 supplementation (24).
These observations suggest that
the current criterion for vitamin
Terms
Univariate
Multivariable (all covariates)
Stepwise regression
OR (95% CI)
OR (95% CI)
adjusted OR (95% CI)
D deficiency (<20 ng/ml) of the
Treatment arm
Institute of Medicine (IOM) may
Active
1
1
–
be a suboptimal vitamin D levPlacebo
1.03 (0.62–1.70)
0.7 (0.4–1.29)
–
el for pregnancy-related adverse
First and third trimester vitamin D
events such as preeclampsia. Our
Low-low
1
1
1
observation is also consistent with
Low-high or high-low
0.62 (0.37–1.04)
0.68 (0.37–1.28)
0.79 (0.45–1.38)
the contemporary understanding
High-high
0.19 (0.06–0.6)
0.25 (0.07–0.87)
0.28 (0.08–0.96)A
of preeclampsia as arising from a
Maternal age (yr)
preclinical phase of aberrant pla<35
1
1
–
centation in early pregnancy (25).
≥35
0.78 (0.27–2.24)
0.96 (0.27–3.3)
–
These data suggest that earlier
1.05 (1.02–1.08)
1.04 (1.002–1.07)
1.04 (1.01–1.07)B
Maternal BMI at first appointment
2
supplementation with vitamin D,
(kg/m )
even prior to implantation of the
Maternal marital status
embryo, may be needed to improve
Not married/divorced
1
1
–
vitamin D status in pregnant womMarried
0.52 (0.3–0.88)
0.7 (0.33–1.60)
Annual family income
en to prevent preeclampsia, a
<$50,000
1
1
–
notion that should be examined in
≥$50,000
0.75 (0.4–1.4)
1.4 (0.77–2.5)
–
a clinical trial.
Unknown or refused to report
1.4 (0.6–3.4)
1.36 (0.7–2.6)
–
Our gene expression substudy
Gravidity
identified a set of vitamin D–assoMultigravid
1
1
1
ciated genes related to preeclampNulligravid
1.37 (0.82–2.27)
1.7 (0.9–3.0)
1.70 (1.003–3.03)
sia, and network-based closeness
Clinical centers
demonstrated their connectivity
Site 1
1
1
1
to known vitamin D–signaling
Site 2
1.01 (0.49–2.06)
0.60 (0.22–1.5)
0.69 (0.32–1.49)
pathways, indicating the functionSite 3
2.05 (1.12–3.7)
0.99 (0.39–2.5)
1.52 (0.79–2.92)
al cohesiveness of vitamin D to
Race/ethnicity
the preeclampsia disease module.
White/mixed European descent
1
1
–
Most of the genes in the replicatBlack/African-American
1.65 (0.94–2.9)
1.07 (0.47–2.4)
–
ed module were associated with
Other
1.2 (0.55–2.6)
0.95 (0.37–2.4)
–
maternal systemic changes in
Maternal education level
Lower than college
1
1
1
immune (innate and humoral) and
College and above
0.36 (0.18–0.7)
0.43 (0.17–1.08)
0.4 (0.21–0.84)C
inflammatory responses. Among
the functional interactions, one of
Categories of 25OHD levels: high-high, subjects who had ≥30 ng/ml at randomization and in the third
the identified biological processes
trimester; high-low, subjects who had ≥30 ng/ml at randomization but <30 ng/ml in the third trimester; lowhigh, subjects who had <30 ng/ml at randomization but ≥30 ng/ml in the third trimester; low-low, subjects
is negative regulation and producwho had <30 ng/ml at both time points. AP = 0.04, BP = 0.016, and CP = 0.015.
tion of IL-10 expression. IL-10 is
an antiinflammatory cytokine that
also mediates innate and humoral immune responses. Decreased
IL-10 levels in placenta and in serum of women with preeclampsia
preeclampsia. Our data are consistent with the NICHD trial’s conhave been observed (26, 27). 1,25(OH)2D3 decreases the synthesis
clusion that a level of 40 ng/ml of circulating 25OHD is required
to support maximum 1,25(OH)2D production during pregnancy (8,
of IL-12 and IL-23 and increases the production of IL-10 by DCs
(28). This effect results in a decrease in Th1 cell responses, pro23). In the NICHD trial, 4,000 IU versus 2,000 and 400 IU vitaducing more Tregs and a Th2 profile that favors a state of immune
min D were given after 12 to 16 weeks of gestation, with 4,000 IU
tolerance to the fetus in the mother (29). IL-10 has also been
having the greatest effect on reducing the composite rate of pregimplicated in placental angiogenesis, growth, and remodeling and
nancy comorbidities. Furthermore, across the treatment arms of
in blunting hypoxic injury at the maternal-fetal interface (29, 30).
this trial (400, 2,000, and 4,000 IU vitamin D), there was a trend
Additionally, the identified preeclampsia module of replicated
toward a significant effect on the odds of pregnancy hypertensive
genes was significantly close and connected to the known IL-10
disorder including preeclampsia after controlling for race (P =
pathways in the interactome (P ≤ 0.0001).
0.05) (8). The observed effect is consistent with the findings of a
Why was therapy with vitamin D not successful in modifying
recent trial of vitamin D supplementation (60,000–480,000 IU
the incidence of preeclampsia in the VDAART or in previous studdose determined by a baseline 25OHD of >20, 10–20, and <10
ies? It is possible that vitamin D supplementation and the subseng/ml; 49% <10 ng/ml) after 20 weeks of gestation (19). As with
quently increased maternal vitamin D metabolites are not importthe NICHD trial, we did not observe any adverse events due to

Table 2. Logistic regression; effects of treatment arm and vitamin D levels on preeclampsia
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Figure 2. Dose-response association between maternal serum 25OHD concentrations at 10 to 18 weeks of
gestation and the corresponding predicted probability of
preeclampsia derived from a logistic regression model
adjusted for the identified confounders (Table 2). The gray
zone indicates 0.95 confidence bands (Npreeclampsia= 67, Nhealthy
= 749). The minimum predicted risk for the population
under study relative to the distribution of pregnant women
(vertical tick marks on the x axis) falls at the concentrations
of 40 to 50 ng/ml serum vitamin D.

ant in the modification of pathophysiologic alterations involved
in the development of preeclampsia. However, the fact that the
observed association of maternal vitamin D levels with a risk of
preeclampsia was reported in several other studies under different
study conditions (5, 8) leads us to deduce that the observed association in the VDAART results is worthy of further investigation,
and that conclusion is supported by our gene expression study.
The timing of vitamin D administration and achievement of
optimal vitamin D concentration are important. Immunologic evidence, detection of early biomarkers, as well as aberrant placental
development and function suggest that preeclampsia is a disorder
of early placentation (28, 31–35). Sufficient vitamin D levels need
to be present at the time of implantation and placentation, the 2
stages in which maternal-fetal immune interfaces play an important role in preeclampsia (36, 37). A significant effect of vitamin
D3 on human extravillous trophoblast invasion in early pregnancy was observed at a concentration of 40 ng/ml (38). Our gene
expression substudy showed the existence of distinctive biological
processes consistent with preeclampsia as early as the tenth week
of pregnancy in women with low vitamin D status who went on
to develop preeclampsia compared with what was observed in the
vitamin D–sufficient matched controls. These observations are

Table 3. Clinical characteristics of the genomic study cohorts
Characteristics

Gestational age (wk), range
Age in years, mean (SD)
Race (n)
White
Black
Other
Serum 25OHD (ng/ml)
Mean (SD)
Missing (n)

Discovery cohort (VDAART)
Preeclampsia
(n = 47)

No preeclampsia
(n = 110)

10–18
25.8 (5.0)

10–18
26.6 (5.1)

17
22
8

42
61
7

19.7 (8.3)
–

24.4 (14.5)
–

suggestive of the evolution of systematic immunologic alterations
at the earliest placental stage and prior to the time of enrollment
in the VDAART. On the contrary, those with vitamin D sufficiency at trial entry (21.8%) and who maintained that status through
their late pregnancy demonstrated a considerably lower risk of
preeclampsia. Although vitamin D is implicated in the pathophysiology of preeclampsia, it is possible that the role of vitamin D is
mediated by other interacting factors (environmental or genetic),
such that a subgroup of pregnant women with low vitamin D status
might achieve the greatest benefit from this therapy. The observed
variability in a dose-response association between maternal vitamin D levels and risk of preeclampsia, particularly at lower concentrations, supports this notion (Figure 2). It should also be noted
that the 4,000 IU dose of vitamin D3 in the VDAART resulted in a
sufficient level of serum vitamin D (≥30 ng/ml) in only 74% of the
pregnancies at 32 to 38 weeks of gestation, which is less than the
82% at 1 month prior to delivery in the NICHD trial on a similar
dose (23). The results of these 2 studies highlight the latest emerging evidence that higher supplementation doses (2,000–6,000
IU/day) than the current recommendation of 400 to 600 IU/day,
particularly in the absence of adequate sun exposure or other highrisk conditions of vitamin D deficiency, might be required to support sufficient levels throughout
pregnancy. While the current
evidence from randomized controlled trials (RCTs) is not sufficient to support 25OHD screenReplication cohort (OMEGA)
ing and high-dose vitamin D
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Figure 3. Gene expression study flow chart.
Summary of analysis approach and findings
on gene expression analysis, through discovery
and replication stages. Gene expression study
was conducted using RankPord to identify
differentially expressed genes in both discovery
and replication cohorts (N = 157 and 30, respectively). PE, preeclampsia; DE, differentially
expressed; VDGS, vitamin D gene signatures;
PEGS, preeclampsia gene signatures; VDGSPE,
vitamin D gene signatures associated with
preeclampsia; rVDGSPE, replicated vitamin D
gene signatures associated with preeclampsia;
PPI, protein-protein interaction.

plementation, prepregnancy supplementation strategies such as a
high dose of vitamin D3 in addition to individualized supplementation doses should be considered, and frequent 25OHD measurements during pregnancy are recommended (41). These concepts
need to be definitively tested in a prepregnancy clinical trial in a
population of women at high risk of preeclampsia.
A limitation of the VDAART as well as other RCTs of vitamin
D supplementation during pregnancy was that subjects with vitamin D sufficiency, i.e., those with a level above 30 ng/ml, were not
screened and were excluded from the trial. While this approach
might have affected the efficacy of vitamin D supplementation, it
provided the opportunity to obtain valuable knowledge by allowing us to compare the pregnant women with vitamin D sufficiency
with those with vitamin D insufficiency in terms of their risk of
preeclampsia occurrence and to identify potential mechanisms of
preeclampsia in early pregnancy. It is noteworthy that a maternal
or paternal history of allergic diseases has not been recognized as
a risk factor for preeclampsia; nevertheless, this inclusion criterion for the VDAART might limit the broad generalizability of our
results in certain populations of pregnant women.
In conclusion, 4,400 IU daily supplementation of vitamin D
initiated at 10 to 18 weeks of gestation did not show a protective
effect against preeclampsia in our ITT analysis; however, vitamin
D sufficiency (≥30 ng/ml) at randomization and at 32 to 38 weeks
of gestation was associated with a significant (P = 0.04) effect on
reducing the risk of preeclampsia development. This observation
and the identified peripheral blood gene expression patterns of
preeclamptic women showing immune gene activation at 10 to
18 weeks of gestation highlight the importance of vitamin D sufficiency in early pregnancy.
4708

jci.org   Volume 126   Number 12   December 2016

Methods

VDAART design, participants, interventions, and oversight. The VDAART
was a randomized, double-blind, placebo-controlled clinical trial of
vitamin D supplementation (4,000 IU vitamin D plus a multivitamin
with 400 IU vitamin D daily) versus placebo (placebo pill plus a multivitamin with 400 IU vitamin D daily) for pregnant women with a high
risk of atopic disease in their family; the goal of the trial was to prevent
asthma in children as well as predefined pregnancy outcomes, including
preeclampsia. Participants were 10–18 weeks pregnant and between the
ages of 18 and 40 years when recruited at obstetric clinics at 3 centers in
the United States: Boston University Medical Center in Boston, Massachusetts; Washington University in St. Louis, Missouri; and Kaiser Permanente Southern California Region in San Diego, California.
Eligible participants were screened between October 2009 and
July 2011 and enrolled if they met the eligibility criteria. Compliance
with daily pill taking during pregnancy was monitored via the Medical Event Monitoring System (MEMS) (www.aardexgroup.com). The
Data and Safety Monitoring Board (DSMB), convened by the National Heart, Lung, and Blood Institute (NHLBI), met every 6 months to
review recruitment, adherence, adverse events, data quality, and protocol changes. Details of the trial design and protocol as well as further
information on the screening, random allocation and blinding process, compliance assessment, statistical power, and trial monitoring
have been published previously (24, 42). The results of the trial were
prepared and reported in accordance with the Consolidated Standards
of Reporting Trials (CONSORT) guidelines.
VDAART and eligibility. The VDAART (www.vdaart.com)
was sponsored by the NHLBI and registered at ClinicalTrials.gov
(NCT00920621). The VDAART involved pregnant women with singleton pregnancies at 10 to 18 weeks of gestation, who were enrolled in
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Figure 4. Functional annotation,
tissue specificity, and PPI network
mapping of vitamin D signatures
associated with preeclampsia
obtained from the gene expression
study. GO functional enrichment
analysis was based on a hypergeometric test with an FDR adjustment
for multiple testing of the identified
pathways.

a multicenter, randomized trial for assessment of the defined outcome
of pregnancy after receiving either vitamin D (cholecalciferol, 4,000
IU/day, equivalent to 100 μg/day) or placebo. All pregnant participants
received prenatal vitamins containing 400 IU (10 μg/day) of cholecalciferol; thus, the vitamin D treatment arm received a total of 4,400 IU/
day (110 μg/day), and the placebo arm received 400 IU/day (10 μg/
day). The pregnant women’s clinical course was followed prospectively
from randomization (10–18 weeks) to the end of the pregnancy and for
investigation of predefined pregnancy outcomes including preeclampsia, preterm birth, and term delivery. The inclusion criteria were as
follows: (a) Maternal history or biological paternal history of asthma,
eczema, or allergic rhinitis. Pregnant women were considered asthmatic or allergic if they gave a positive answer to the direct question in the
enrollment questionnaire or any subsequent monthly questionnaire;
(b) gestational age between 10 and 18 weeks at the time of randomization; (c) maternal age between 18 and 39 years; (d) not a current smoker
(defined as not having smoked for at least 1 month prior to enrollment)
and not a user of other nicotine products (e.g., nicotine patch) for at
least 1 month prior to enrollment; (e) English- or Spanish-speaking; (f)
intention to participate in the trial throughout the pregnancy.
The exclusion criteria were as follows: (a) Gestational age beyond
18 weeks; (b) presence of any of the following chronic medical conditions: (i) hypertension (on medication); (ii) diabetes mellitus; (iii) parathyroid disease; (iv) uncontrolled thyroid disease; (vi) kidney stones;
or (vii) sarcoidosis; (c) intake of vitamin D supplements containing
more than 2,000 IU/day of vitamin D3; (d) multiple gestational pregnancy; (e) pregnancy achieved by assisted reproductive techniques
(e.g., IUI, IVF); (f) current use of illicit drugs (defined as any use in
the past 6 months prior to enrollment); (g) previous enrollment in the
VDAART for a prior pregnancy; (h) any major fetal anomalies detected
prior to delivery; (i) patient health questionnaire (PHQ-9) depression
scale of 15 or higher; (j) any condition, in the opinion of the clinical

center’s principal investigator, that would inhibit compliance with the
study medications or prohibit long-term participation in the trial.
Assessment of compliance: MEMS. The primary measure of compliance with pill taking was monitored via the MEMS (AARDEX Group;
http://www.aardexgroup.com), which consists of a pill bottle equipped
with special cap that includes an electronic microchip that stores the
date and time of each opening of the bottle. Each monitor recorded
the time and date of each opening and closing of the container through
integrated microcircuitry. The MEMS stores up to 3,800 medication
events in nonvolatile, electrically erasable, programmable read-only
memory (EEPROM), allows wireless data transfer, fits standard pharmacy bottles, provides 36 months of battery life, and is water resistant and CE marked. Monitors were designed for usage by 1 patient
with 1 drug. A reader allowed transfer of the dose-timing data from
the MEMS to a Microsoft Windows–based computer. Data from the
MEMS were downloaded at the monthly in-person prenatal visits and
after delivery. The data from the prenatal follow-up visits were used
to provide feedback to the participant, reinforcing those participants
with good adherence and providing extra teaching and encouragement for those with suboptimal adherence. The data from both prenatal follow-up and postnatal downloads were used to derive a summary
adherence measure, to be used as a covariate in our analyses. In addition to the information obtained from the MEMS, the 25OHD levels
detected from the baseline measurement and at the third-trimester
visits provided excellent adherence information for this trial.
Data collection on the VDAART subjects. The research staff met
with the participants monthly, in conjunction with their regularly
scheduled obstetrical visits. At these visits, a short maternal health
questionnaire was administered, MEMS cap information was downloaded, and study medication and prenatal vitamins were refilled. At
these monthly prenatal visits, the research staff conducted monthly
reviews of electronic medical records to check for pregnancy complijci.org   Volume 126   Number 12   December 2016
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Figure 5. LCC genes (143 genes, highlighted in red)
corresponding to the “observable preeclampsia module” among the replicated differentially expressed
genes (N = 348) and their biological processes. The
connectivity of the replicated signatures was explored
by mapping onto functional protein-protein interaction
networks from HumanNet v.1.
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Figure 6. Connection among the vitamin D– and IL-10–signaling pathway genes (blue and yellow modules, respectively) within the module. Only the
direct connections between vitamin D and IL-10 pathway genes within the module are shown. The size of the circles corresponds to the degree of genes
in the interactome. The closeness of the vitamin D– and IL-10–signaling pathways to the LCC is based on the observed shortest path between each set of
genes and the LCC.

cations; these were logged, and a severe adverse event (SVE) form or
an adverse event form was completed as applicable. At 32 to 38 weeks
of gestation, in addition to the monthly routine, a blood draw, skin
pigmentation determination, and several of the questionnaires that
were administered at the enrollment visit were repeated. At delivery,
cord blood was collected, and the research staff collected information regarding the type of delivery, birth weight of the baby, and other
anthropometric measures from the delivery records.
Study outcome and main predictor measurements. The occurrence
of preeclampsia was a prespecified secondary outcome of the trial and

an adverse event. Pregnant women with known chronic hypertension
were excluded from entry into the VDAART. Every month, study coordinators performed a medical record review for cases of preeclampsia
as part of the protocol for identifying SVEs in the trial. Medical records
were abstracted for all participants after delivery. A committee of
4 board-certified obstetricians conducted a blinded review of 276
abstracted charts of subjects with a noted diagnosis of hypertension,
proteinuria, or preeclampsia to determine preeclampsia status. The
diagnosis of preeclampsia at the time of the record reviews was based
on the American Congress of Obstetricians and Gynecologists (ACOG)
jci.org   Volume 126   Number 12   December 2016
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Table 4. Average distances between the preeclampsia module and vitamin D receptor (VDR) and IL-10 pathways
Pathway closeness to PE module

Average distance

Random distance

SD

Z score

IL-10 pathway vs. preeclampsia module
VDR pathway vs. preeclampsia module

2.45
2.53

2.80
2.70

0.04
0.045

–8.60
–3.80

guidelines (43), which included the identification of high blood pressure (BP) and either proteinuria (≥300 mg per 24-hour collection or
≥1+ on a urine dipstick) or the presence of elevated liver enzymes, high
platelet count, headache, or visual disturbances after 20 weeks of gestation. High BP was diagnosed for participants who had a systolic BP
of 140 mmHg or higher, a diastolic BP of 90 mmHg or higher, or both,
with a second elevated measurement noted in the medical record at
least 6 hours after the first measurement was taken. Consequently,
preeclampsia was diagnosed in 67 participants. Total 25OHD levels
were measured using a chemiluminescence assay on a DiaSorin LIAISON machine at the data coordination center (DCC). We performed
the 25OHD TOTAL assay, which has shown an excellent correlation
with the DiaSorin 25OHD RIA assay, which has been used to defined
reference levels. This method has also exhibited better concordance
with liquid chromatography–tandem mass spectrometry (LC-MS/MS)
results as compared with other available methods (44). Additionally,
using specific polyclonal antibodies, this method avoids the previously
observed racial differences in vitamin D–binding protein (VDBP) concentrations that are most likely due to monoclonal assay bias (45, 46).
For quality control, our laboratory used the US National Institute of
Standards and Technology (NIST) level 1 protocol.
Gene expression substudy. Participants of the preeclampsia microarray study comprised a nested case-control group (N = 157) selected
from among participants of the VDAART. Of the 67 women with preeclampsia, 47 (70.14%) had a suitable RNA sample available at entry
into the trial (10–18 weeks of gestation) and participated in the gene
expression substudy. Controls were chosen from the VDAART subjects matched for age (within 5 years), race, and study center, such that
each subject had 2 matched controls. Once the initial set of matched
study subjects and controls was formed, additional controls were
incorporated to enhance the range of 25OHD concentrations present
among the control subjects (total Ncontrols= 110). In a post-matching
comparison, we found no significant difference (all P values >0.05) in
age, race, or maternal gestational age in early pregnancy among the 47
preeclampsia subjects and the 110 normal controls.
RNA isolation and microarray processing. Total RNA was isolated from whole blood using the QIAGEN PAXgene Blood RNA
Kit according to the manufacturer’s protocol. The GLOBINclear Kit (Ambion) was used to remove α and β globin mRNA
from the sample to increase the sensitivity of the gene expression assays by improving the detection rate of expressed genes.
The RNA was quantified using the Nanodrop 8000 and checked
for high integrity before preparation of cDNA. The integrity of RNA
samples was assessed using the Agilent 2100 Bioanalyzer, and purity of the samples was confirmed using the NanoDrop spectrophotometer and RNA integrity number (RIN ≥8). Gene expression was
assessed using the Affymetrix Human Gene 1.0 ST Array. Biotinylat4712
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ed cRNA was prepared according to the manufacturer’s protocol,
and hybridization was processed according to the protocol for the
GeneChip Hybridization Control Kit (http://www.affymetrix.com/
estore/browse/products.jsp;jsessionid=7F717F80BE253ABBF6155B
16AC95C6F9?navMode=34000&productId=131453&navAction=
jump&aId=productsNav#1_1).
After image production and processing, an expression set with
33,297 probes and 157 samples, collected at 10 to 18 weeks of gestation (enrollment), were generated, representing the 47 subjects
with preeclampsia and the 110 unaffected normal pregnant women. In order to check the quality of the arrays, quantiles of expressions were examined before and after normalization. Background
adjustment, log2 transformation, and quantile normalization were
performed using the robust multiarray analysis (“rma”) function in
R BioConductor’s “affy” library to minimize nonbiological variability among arrays. Principal component (PC) analysis of samples was
done to identify any extreme outlier. Thereafter, phenotypes of interest were merged with the expression set. Probes were annotated using
the annotation package for Bioconductor pd.hugene.1.0.st.v1 and
confined to annotated probes of autosomal chromosomes (19,137
probes). The interquartile range (IQR) filter (values of IQR including 80% of the probe expressions) was implemented in R using the
“genefilter” package from Bioconductor to remove expressions
showing little changes within arrays (47). This process resulted in
an expression set of 15,309 probes belonging to 157 samples collected at 10 to 18 weeks of pregnancy, representing 47 preeclampsia cases
and 110 women. To capture the expression heterogeneity, surrogate
variable analysis was conducted by applying the surrogate variable
analysis (SVA) function to the expression data. Accordingly, 16 surrogate variables (SVs) were identified and expression data adjusted for
12 batches uncorrelated to the main predictor of interest, i.e., vitamin
D serum levels in early pregnancy. Thereafter, differential expression
analysis was carried out using the Bioconductor package “RankProd,”
which implements the rank product method for identifying differentially expressed genes (48).
The data discussed in this article were deposited in the NCBI’s
Gene Expression Omnibus (GEO) database (GEO GSE85307;
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=epajoakqppkvbub&acc=GSE85307).
Microarray validation by quantitative reverse transcription PCR.
To ensure internal validity, the top ranked up- or downregulated
genes by RankProd from the replication results were chosen for validation by quantitative reverse transcription PCR (qRT-PCR), and
qRT-PCR was performed.
Replication cohort. A population selected to replicate the gene
expression results in the VDAART was obtained from a nested
case-control study of preeclampsia (Ncases= 16 and Ncontrols= 16) with-
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in the OMEGA study, a prospective cohort study designed to assess
dietary and other lifestyle risk factors of preeclampsia and other medical complications of pregnancy (49). Participants were nulliparous
women, who initiated prenatal care at the Swedish Medical Center in
Seattle, Washington, USA. Transcriptional data for 2 cases were of low
quality and therefore omitted from the analysis.
Quality control of the replication data. Gene expression of subjects
was profiled using Affymetrix GeneChip Arrays. Quantiles of raw
expression and principal compontents (PCs) across arrays were examined before and after background adjustment normalization and log2
using the “rma” function in the R “affy” library. Expression data for
2 of the samples were identified as outliers and removed, and quantile-normalized and background-adjusted expression data as well as
PCs were reexamined. The results were compared by running the
“QCReport” function in the R library’s “affyQCReport.” The microarray expression data were annotated using “hgu133plus2,” available
on Bioconductor. The annotated expression from autosomal chromosomes was included in the analysis. The final expression data set
contained 40,003 rows of background-adjusted, log2-transformed,
rma-summarized, and quantile-normalized expression data for 14
preeclampsia cases and 16 controls.
Statistics. In accordance with the ITT paradigm, data for all women (N = 816) were analyzed according to the group to which they were
randomly assigned (Figure 1). For demographic data, continuous variables were compared using the appropriate 2-tailed t test or χ2 test, and
a P value of less than 0.05 was considered statistically significant.
A vitamin D level of 30 ng/ml (75 nmol/l) was used to differentiate between high and low levels (high-high, high-low or low-high, and
low-low) at both study time points. Selection of this cutoff was mostly
based on the observations of several studies designed to investigate the
relationship between serum parathyroid hormone (PTH) and 25OHD
levels in adults. These studies have shown that the suppression of PTH
reaches a plateau when the 25OHD level approximates 30 ng/ml (50).
Of note, it has been demonstrated that during pregnancy, serum PTH
levels are not different from those of nonpregnant women (51, 52).
Two ITT analyses were performed: (a) For the primary outcome
assessment, we used logistic regression analysis, controlling for a
priori covariates or potential confounders (associated with primary
outcome and the main variable of vitamin D status at a significance
level of 0.2; Table 2 and Supplemental Table 6) including gravidity,
age, race, BMI, study group designation, education level, income, and
study center; (b) within-group and group-collapsed trend tests of categorical 25OHD concentration effects on preeclampsia development
were applied. Finally, we evaluated the dose-response association
between maternal vitamin D serum concentrations at 10 to 18 weeks
of gestation and risk of preeclampsia after adjustment for the informative variables identified in the primary outcome analysis (Table 2). For
all of the ITT analyses, 2-sided P values of less than 0.05 were considered statistically significant.
Transcriptomic variations related to preeclampsia. SV analyses
were conducted, and tests for differential gene expression included
an adjustment for expression heterogeneity. Differential expression
analysis was carried out using the Bioconductor “RankProd” package,
which implements the rank product method for identifying differentially expressed genes (48). Differentially expressed (up- or downregulated) genes were identified through permutation analysis, after setting the percentage of the false prediction threshold for which the FDR
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was less than 0.05. The number of permutations used was set as the
package default value. We separately identified genes associated with
high/low vitamin D status (at a cutoff of 30 ng/ml) and preeclampsia
case status and then identified the overlap of these 2 gene modules.
We replicated the overlap in our second case-control study using the
rank product method. Those genes having a P value of less than 0.05
in the replication population were considered for further investigation
in the network and pathway analysis as well as for literature curation
for their relationship to preeclampsia.
In addition to the GeneCards (53) and MetaCore databases
(https://lsresearch.thomsonreuters.com/pages/solutions/1/metacore)
(overall 673 annotations), the replicated gene signatures were manually curated in order to validate their connection to preeclampsia according to the scientific literature and previous preeclampsia research.
Using the Human Protein Atlas (HPA), the subset of replicated signatures with evidence of tissue-specific expression in placenta was identified (54). Figures 3 and 4 provide an overview of our approach and a
summary of the results.
Molecular and functional interaction gene networks. The connectivity of the replicated signatures was explored by mapping onto functional protein-protein interaction networks from HumanNet v.1 (55). The
identified gene set (preeclampsia module) was subsequently used to
construct the “observable preeclampsia module,” defined as the largest connected component (LCC) of the replicated signature genes (17).
Thereafter, the connectivity of this module to the known vitamin D–
and IL-10–signaling pathways using available data from the National
Cancer Institute’s (NCI’s) Pathway Interaction Database (http://pid.
nci.nih.gov) was explored. GO enrichment analysis was conducted to
investigate the biological processes involved in the identified modules
(56). Further details on the methods are provided in Figure 2.
Molecular interaction networks and pathway enrichment analysis.
To understand the functional relationships underlying the set of replicated differentially expressed genes, we explored their connectivity
in the HumanNet functional network (55). HumanNet uses a naive
Bayes approach to weight different types of evidence together into
a single interaction score focusing on data collected from humans,
yeast, worms, and flies. We mapped the differentially expressed
genes encoding proteins in the interactome and identified the LCC
(or “observable preeclampsia module,” Figure 5) (17). Furthermore,
we tested the closeness of the observable preeclampsia module to the
vitamin D and IL-10 pathways, as described below. Ordered functional enrichment for the representative GO terms “biological processed,”
“molecular function,” and “cell component” annotations for both the
replicated gene set and observable preeclampsia module was carried
out with g:Profiler (56, 57). Accordingly, gene group functioning profiling was performed with default options limiting the output to significant results (multiple testing–corrected P < 0.05).
Connectivity of preeclampsia module to vitamin D receptor and IL-10
pathways. We defined vitamin D and IL-10 pathways as reported in
the NCI’s Pathway Interaction and BioCarta databases, respectively
(http://pid.nci.nih.gov). To test whether the observable preeclampsia
module was connected to vitamin D and IL-10 pathways, we measured the closeness between the 2 sets of genes and compared this
parameter with that having a random expectation of closeness (Figure
6). The assumption behind this exercise was that, even if the genes
did not overlap between the preeclampsia module and vitamin D and
IL-10 pathways, they should be localized in the same neighborhood
jci.org   Volume 126   Number 12   December 2016
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of the interactome. The closeness was computed as the average of all
possible shortest paths between 2 sets of genes, according to the following formula:

				(Equation 1)
In this formula, d(s, t) is the shortest path from a gene s in the preeclampsia module (Pm), and a gene t of the interest pathway (Pw), and
NPm and NPw denote the number of genes in each set. To determine the
significance of this quantity, we selected NPm genes at random in the
network and determined the average distance (Avg distrand) to the Pm.
This exercise was repeated 1,000 times, and the significance was evaluated by computing the Z score as follows:

				(Equation 2)
In this formula, μ(Avg distrand) and ϭ(Avg distrand) denote the mean
value and SD of the random expectation. Any distance with a Z score
lower than –1.65 (i.e., modules closer than expected) was deemed significant; as such, a cutoff corresponded to P ≈ 0.05 in the case of a normally distributed variable.
Study approval. The VDAART was approved by the IRBs of the
participating institutions (Washington University in St. Louis, Boston Medical Center, Kaiser Health Care San Diego) and Brigham and
Women’s Hospital, and written consent was obtained from all participating pregnant women at their first enrollment visit. See the Supplemental material for the list of DSMB and DCC members (Supplemental Acknowledgments).
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